{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:55:36Z","timestamp":1791042936377,"version":"4.1.0"},"posted":{"date-parts":[[2026,8,20]]},"group-title":"Cancer Biology","reference-count":65,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Institutes of Health","award":["R01HL151579"],"award-info":[{"award-number":["R01HL151579"]}]},{"award":["R01HL151579"],"award-info":[{"award-number":["R01HL151579"]}],"id":[{"id":"https:\/\/ror.org\/001d55x84","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,8,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are hematopoietic stem cell cancers that result in aberrant trilineage myeloid cell proliferation, bone marrow fibrosis, and increased risk of acute myeloid leukemia. MPNs are driven by deregulated activity of the JAK2 kinase, induced by mutations in the\n                  <jats:italic>JAK2<\/jats:italic>\n                  ,\n                  <jats:italic>CALR<\/jats:italic>\n                  , and\n                  <jats:italic>MPL<\/jats:italic>\n                  genes, but approved JAK2 inhibitors primarily offer palliative effects, not remission. Cell models that demonstrate MPN oncogene driven JAK2 activity requisite for cell proliferation are important research tools for the development of anti-JAK2 and anti-JAK2 signaling therapeutics for MPN. SET2 and UKE1 cells are two such cell lines, as they express JAK2-V617F, one of the major driving mutations of MPN, and require signaling by JAK2 for their growth and viability. These cell lines are AML cell lines that were derived from patients with a previous diagnosis of MPN before they developed AML. Our previous studies demonstrated that the SHP2 phosphatase may be a therapeutic target for MPNs, and here we report our identification and characterization of an activating point mutation of SHP2 (encoded by the\n                  <jats:italic>PTPN11<\/jats:italic>\n                  gene), SHP2-F71L, in UKE1 cells. Given SHP2 functions downstream of JAK2 and mediates JAK2 activation of RAS, we set out to determine the effect of mutational activation of SHP2 on the sensitivity of MPN model cells to JAK2 inhibition. We used CRISPR-Cas9 to edit this mutation in UKE1 cells back to wildtype such that these cells only express wildtype SHP2. These cells exhibited enhanced sensitivity to SHP2 inhibition and, notably, enhanced sensitivity to the JAK2 inhibitor ruxolitinib. This altered sensitivity was reverted by exogenous expression of SHP2-F71L but not SHP2-WT, indicating expression of an activated SHP2 may alter sensitivity to JAK2 inhibition in MPN model cells. We further explored this by genetically editing SET2 cells to express SHP2-F71L but observed no change in SHP2 inhibitor or JAK2 inhibitor sensitivity in cells with a SHP2-F71L encoding allele of\n                  <jats:italic>PTPN11<\/jats:italic>\n                  . Using the cytokine dependent BaF3 cell line where deregulation of JAK2 signaling by expression of JAK2-V617F induces cytokine independent transformation that remains dependent on this JAK2 signaling, we observed no effect of the expression of an activated SHP2 mutant on the sensitivity of the growth and viability of these cells to ruxolitinib. Recent studies have demonstrated activation of RAS signaling can antagonize JAK2 inhibition in pre-clinical MPN models, and the presence of RAS pathway mutations associates with patients whose disease advances on ruxolitinib therapy. Such mutations include activating mutations in\n                  <jats:italic>PTPN11<\/jats:italic>\n                  , as SHP2 is an upstream activator of RAS signaling. Our results suggest that activating\n                  <jats:italic>PTPN11<\/jats:italic>\n                  mutations have the potential to desensitize the effects of JAK2 inhibition therapy in patients undergoing therapy and may be dependent on unknown cell and molecular profile contexts.\n                <\/jats:p>","DOI":"10.64898\/2026.08.19.744423","type":"posted-content","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T21:30:29Z","timestamp":1787261429000},"source":"Crossref","is-referenced-by-count":0,"title":["Modulation of the sensitivity to ruxolitinib-mediated JAK2 inhibition by mutationally activated SHP2 exhibits cell context dependency in pre-clinical models of myeloproliferative neoplasms"],"prefix":"10.64898","author":[{"given":"Tegan M.","family":"Rowsell","sequence":"first","affiliation":[{"name":"Department of Molecular Oncology Moffitt Cancer Center Tampa, FL USA 33612"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0864-4137","authenticated-orcid":false,"given":"Garima","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Molecular Oncology Moffitt Cancer Center Tampa, FL USA 33612"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8336-8032","authenticated-orcid":false,"given":"Lucia","family":"Mazzacurati","sequence":"additional","affiliation":[{"name":"Department of Molecular Oncology Moffitt Cancer Center Tampa, FL USA 33612"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8672-5907","authenticated-orcid":false,"given":"Narmin E.","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Molecular Oncology Moffitt Cancer Center Tampa, FL USA 33612"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2317-931X","authenticated-orcid":false,"given":"Gary W.","family":"Reuther","sequence":"additional","affiliation":[{"name":"Department of Molecular Oncology Moffitt Cancer Center Tampa, FL USA 33612"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026100308300910000_2026.08.19.744423v1.1","doi-asserted-by":"crossref","first-page":"e578","DOI":"10.1097\/HS9.0000000000000578","article-title":"Functional Consequences of Mutations in Myeloproliferative Neoplasms","volume":"5","year":"2021","journal-title":"Hemasphere"},{"key":"2026100308300910000_2026.08.19.744423v1.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2210"},{"key":"2026100308300910000_2026.08.19.744423v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406186"},{"key":"2026100308300910000_2026.08.19.744423v1.4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative Neoplasms: A Contemporary Review","volume":"1","year":"2015","journal-title":"JAMA Oncol"},{"key":"2026100308300910000_2026.08.19.744423v1.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-695940"},{"key":"2026100308300910000_2026.08.19.744423v1.6","doi-asserted-by":"crossref","unstructured":"Bose P , Xiao Z , Hasselbalch HC , Prchal JT , Duan M , Yacoub A , et al. Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms. Curr Hematol Malig Rep. 2025;20:9.","DOI":"10.1007\/s11899-025-00752-3"},{"key":"2026100308300910000_2026.08.19.744423v1.7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/10428194.2025.2594038","article-title":"Interferon alpha in myeloproliferative neoplasms: evidence and practical considerations for clinical care","volume":"67","year":"2026","journal-title":"Leuk Lymphoma"},{"key":"2026100308300910000_2026.08.19.744423v1.8","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41375-026-02882-w","article-title":"A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha","volume":"40","year":"2026","journal-title":"Leukemia"},{"key":"2026100308300910000_2026.08.19.744423v1.9","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood.2025028645","article-title":"Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms","volume":"147","year":"2026","journal-title":"Blood"},{"key":"2026100308300910000_2026.08.19.744423v1.10","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood.2022017416","article-title":"Biology and therapeutic targeting of molecular mechanisms in MPNs","volume":"141","year":"2023","journal-title":"Blood"},{"issue":"Suppl 4","key":"2026100308300910000_2026.08.19.744423v1.11","first-page":"30","article-title":"Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives","volume":"100","year":"2025","journal-title":"Am J Hematol"},{"key":"2026100308300910000_2026.08.19.744423v1.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-176875"},{"key":"2026100308300910000_2026.08.19.744423v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404081"},{"key":"2026100308300910000_2026.08.19.744423v1.14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404845"},{"key":"2026100308300910000_2026.08.19.744423v1.15","doi-asserted-by":"publisher","DOI":"10.1126\/science.6177045"},{"key":"2026100308300910000_2026.08.19.744423v1.16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401608"},{"key":"2026100308300910000_2026.08.19.744423v1.17","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<344::AID-CNCR14>3.0.CO;2-6"},{"key":"2026100308300910000_2026.08.19.744423v1.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00763-x"},{"key":"2026100308300910000_2026.08.19.744423v1.19","unstructured":"DepMap BDPQDdo. DepMap, Broad. DepMap Public 26Q1. Dataset. depmap.org. 2026."},{"key":"2026100308300910000_2026.08.19.744423v1.20","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood.2024026388","article-title":"Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML","volume":"145","year":"2025","journal-title":"Blood"},{"key":"2026100308300910000_2026.08.19.744423v1.21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood.2024027117","article-title":"Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML","volume":"146","year":"2025","journal-title":"Blood"},{"key":"2026100308300910000_2026.08.19.744423v1.22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.23.9312"},{"key":"2026100308300910000_2026.08.19.744423v1.23","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"2026100308300910000_2026.08.19.744423v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"2026100308300910000_2026.08.19.744423v1.25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270"},{"key":"2026100308300910000_2026.08.19.744423v1.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311347"},{"key":"2026100308300910000_2026.08.19.744423v1.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312542"},{"key":"2026100308300910000_2026.08.19.744423v1.28","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27282"},{"key":"2026100308300910000_2026.08.19.744423v1.29","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2023-190216","article-title":"Genetic Deletion or Pharmacologic Inhibition of PTPN11 Impedes the Development and Progression of Myeloproliferative Neoplasms Induced By JAK2V617F and MPLW515L Mutants","volume":"142","year":"2023","journal-title":"Blood"},{"key":"2026100308300910000_2026.08.19.744423v1.30","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-008-9126-y"},{"key":"2026100308300910000_2026.08.19.744423v1.31","doi-asserted-by":"crossref","unstructured":"Rouillard AD , Gundersen GW , Fernandez NF , Wang Z , Monteiro CD , McDermott MG , et al. The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. Database (Oxford). 2016;2016.","DOI":"10.1093\/database\/baw100"},{"key":"2026100308300910000_2026.08.19.744423v1.32","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae1080"},{"key":"2026100308300910000_2026.08.19.744423v1.33","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3080"},{"key":"2026100308300910000_2026.08.19.744423v1.34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1923"},{"key":"2026100308300910000_2026.08.19.744423v1.35","doi-asserted-by":"publisher","DOI":"10.1086\/499925"},{"key":"2026100308300910000_2026.08.19.744423v1.36","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018015875"},{"key":"2026100308300910000_2026.08.19.744423v1.37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-633404"},{"key":"2026100308300910000_2026.08.19.744423v1.38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1407792111"},{"key":"2026100308300910000_2026.08.19.744423v1.39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9859"},{"key":"2026100308300910000_2026.08.19.744423v1.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2007.10.002"},{"key":"2026100308300910000_2026.08.19.744423v1.41","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20061548"},{"key":"2026100308300910000_2026.08.19.744423v1.42","doi-asserted-by":"crossref","unstructured":"Pandey G , Kuykendall AT , Reuther GW . JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation. Blood Cancer J. 2022;12:13.","DOI":"10.1038\/s41408-022-00609-5"},{"key":"2026100308300910000_2026.08.19.744423v1.43","doi-asserted-by":"publisher","DOI":"10.1172\/JCI98785"},{"key":"2026100308300910000_2026.08.19.744423v1.44","doi-asserted-by":"crossref","unstructured":"Winter PS , Sarosiek KA , Lin KH , Meggendorfer M , Schnittger S , Letai A , et al. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. Sci Signal. 2014;7:ra122.","DOI":"10.1126\/scisignal.2005301"},{"key":"2026100308300910000_2026.08.19.744423v1.45","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1038\/s41375-021-01391-2","article-title":"Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy","volume":"35","year":"2021","journal-title":"Leukemia"},{"key":"2026100308300910000_2026.08.19.744423v1.46","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2968-3"},{"key":"2026100308300910000_2026.08.19.744423v1.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-018-0169-1"},{"key":"2026100308300910000_2026.08.19.744423v1.48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06823-9"},{"key":"2026100308300910000_2026.08.19.744423v1.49","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0568-T"},{"key":"2026100308300910000_2026.08.19.744423v1.50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509714102"},{"key":"2026100308300910000_2026.08.19.744423v1.51","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1097\/HS9.0000000000000516","article-title":"Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms","volume":"5","year":"2021","journal-title":"Hemasphere"},{"key":"2026100308300910000_2026.08.19.744423v1.52","doi-asserted-by":"publisher","DOI":"10.1038\/nature11303"},{"key":"2026100308300910000_2026.08.19.744423v1.53","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/bloodadvances.2020002804","article-title":"Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFkappaB pathway inhibition","volume":"6","year":"2022","journal-title":"Blood Adv"},{"key":"2026100308300910000_2026.08.19.744423v1.54","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002175"},{"key":"2026100308300910000_2026.08.19.744423v1.55","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1158\/1078-0432.CCR-23-0372","article-title":"Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations","volume":"30","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026100308300910000_2026.08.19.744423v1.56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60884-1"},{"key":"2026100308300910000_2026.08.19.744423v1.57","doi-asserted-by":"crossref","unstructured":"Mylonas E , Yoshida K , Frick M , Hoyer K , Christen F , Kaeda J , et al. Single-cell analysis based dissection of clonality in myelofibrosis. Nat Commun. 2020;11:73.","DOI":"10.1038\/s41467-019-13892-x"},{"key":"2026100308300910000_2026.08.19.744423v1.58","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1038\/s41375-023-02027-3","article-title":"RAS-pathway mutations are common in patients with ruxolitinib refractory\/intolerant myelofibrosis: molecular analysis of the PAC203 cohort","volume":"37","year":"2023","journal-title":"Leukemia"},{"key":"2026100308300910000_2026.08.19.744423v1.59","doi-asserted-by":"crossref","unstructured":"Reynolds SB , Pettit K , Kandarpa M , Talpaz M , Li Q . Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling. Cancers (Basel). 2023;15.","DOI":"10.3390\/cancers15184654"},{"key":"2026100308300910000_2026.08.19.744423v1.60","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-019-0603-9","article-title":"Prognostic impact of RAS-pathway mutations in patients with myelofibrosis","volume":"34","year":"2020","journal-title":"Leukemia"},{"key":"2026100308300910000_2026.08.19.744423v1.61","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006242"},{"key":"2026100308300910000_2026.08.19.744423v1.62","doi-asserted-by":"publisher","DOI":"10.1038\/ng1156"},{"key":"2026100308300910000_2026.08.19.744423v1.63","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0053"},{"key":"2026100308300910000_2026.08.19.744423v1.64","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/bloodadvances.2019000260","article-title":"The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN","volume":"3","year":"2019","journal-title":"Blood Adv"},{"key":"2026100308300910000_2026.08.19.744423v1.65","doi-asserted-by":"publisher","DOI":"10.1089\/10430340252898984"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.08.19.744423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:30:23Z","timestamp":1791041423000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.08.19.744423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":65,"URL":"https:\/\/doi.org\/10.64898\/2026.08.19.744423","relation":{},"subject":[],"published":{"date-parts":[[2026,8,20]]},"subtype":"preprint"}}